Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
37.44
+0.58 (1.57%)
At close: Apr 23, 2025, 4:00 PM
36.30
-1.14 (-3.04%)
Pre-market: Apr 24, 2025, 4:01 AM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Revolution Medicines stock have an average target of 68.25, with a low estimate of 55 and a high estimate of 87. The average target predicts an increase of 82.29% from the current stock price of 37.44.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 8 | 8 | 7 |
| Buy | 7 | 6 | 6 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $59 | Strong Buy | Reiterates | $59 | +57.59% | Apr 8, 2025 |
| Stifel | Stifel | Strong Buy Maintains $78 → $64 | Strong Buy | Maintains | $78 → $64 | +70.94% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $73 | Strong Buy | Maintains | $72 → $73 | +94.98% | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $80 → $78 | Strong Buy | Maintains | $80 → $78 | +108.33% | Feb 27, 2025 |
| Needham | Needham | Strong Buy Maintains $60 → $59 | Strong Buy | Maintains | $60 → $59 | +57.59% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
1.67M
Revenue Next Year
4.23M
from 1.67M
Increased by 153.62%
EPS This Year
-4.65
from -3.58
EPS Next Year
-4.99
from -4.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 43.6M | 570.2M | ||
| Avg | 1.7M | 4.2M | 115.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,510.8% | 13,369.2% | ||
| Avg | - | 153.6% | 2,622.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.00 | -4.34 | -1.19 | ||
| Avg | -4.65 | -4.99 | -4.53 | ||
| Low | -4.84 | -5.44 | -5.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.